Ascentage Pharma to Announce H1 2025 Results Aug 20
Ticker: AAPG · Form: 6-K · Filed: Aug 7, 2025 · CIK: 2023311
Sentiment: neutral
Topics: results-announcement, corporate-update, filing
TL;DR
Ascentage Pharma (ASC) dropping H1 2025 results & update on Aug 20.
AI Summary
Ascentage Pharma Group International announced on August 7, 2025, that they will report their 2025 six-month interim results and provide a corporate update on August 20, 2025. This information was shared via a press release furnished as Exhibit 99.1 to their 6-K filing.
Why It Matters
Investors and stakeholders will gain insight into the company's financial performance and strategic developments for the first half of 2025.
Risk Assessment
Risk Level: low — This filing is a routine announcement of upcoming financial results and corporate updates, with no immediate material changes or events disclosed.
Key Players & Entities
- Ascentage Pharma Group International (company) — Registrant
- August 7, 2025 (date) — Announcement date
- August 20, 2025 (date) — Results and update date
- Exhibit 99.1 (document) — Press release reference
FAQ
What specific financial results will Ascentage Pharma report on August 20, 2025?
Ascentage Pharma will report their 2025 six-month interim results.
What is the purpose of the press release dated August 7, 2025?
The press release announces that Ascentage Pharma will report its 2025 six-month interim results and provide a corporate update on August 20, 2025.
Under which form is this report filed?
This report is filed under Form 6-K.
What is the filing date of this 6-K report?
The filing date is August 7, 2025.
Where are Ascentage Pharma's principal executive offices located?
Ascentage Pharma's principal executive offices are located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Filing Stats: 202 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2025-08-07 08:15:01
Filing Documents
- ea0252146-6k_ascentage.htm (6-K) — 12KB
- ea025214601ex99-1_ascentage.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 18KB
- 0001213900-25-072827.txt ( ) — 47KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 002-023311 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On August 7, 2025, Ascentage Pharma Group International issued a press release entitled, “Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025”. A copy of the press release is furnished as Exhibit 99.1 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Press Release dated August 7, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: August 7, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3